Psychedelics Startups for the Future of Mental Health. Panel moderated by Cate Lawrence at Tech.eu

-

Discover the future of mental health at the intersection of psychedelics and tech, where digital phenotyping, therapy platforms, and biosynthesis are driving innovation and-breaking down stigma, moderated by Cate Lawrence at Tech.eu.

Key takeaways
  • Digital phenotyping through mobile phone usage can aid in tracking people’s mental health.
  • Psychedelic treatments are promising, but not everyone responds to them and it can be demoralizing.
  • The stigma surrounding psychedelics is still present, but accelerating clinical trials and research will help reduce it.
  • Therapist training is crucial for administering psychedelic treatments, and digital therapy platforms are emerging.
  • The pharma industry is slow to adopt psychedelic treatments, but changes are expected in the next 10 years.
  • Veteran patients have benefited from psychedelic treatments, particularly for PTSD and depression.
  • Biosynthesis and biotech companies are working on novel psychedelic compounds, such as LSD and psilocybin.
  • The-global movement is shifting away from prohibition and towards mainstream acceptance of psychedelics.
  • Synthetic forms of naturally-occurring psychedelics may not be the most effective or sustainable approach.
  • Telemedicine is expanding access to psychedelic treatments, andтю will likely become a standard treatment option.
  • Patient stories and advocacy are crucial for shifting public perception and driving change.
  • The intersection of psychedelics and mental health is complex, with many unaddressed issues, such as addiction and eating disorders.
  • Innovation in the psychedelic space is happening, but it requires investment, infrastructure, and regulatory support.
  • There is a growing demand for psychedelic education and training programs for healthcare professionals.